Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.

Yumiko Akamine, Masatomo Miura, Norio Yasui-Furukori, Midori Kojima, Tsukasa Uno

Department of Hospital Pharmacy, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.

British journal of clinical pharmacology 2012 Mar

filter terms:

This aim of this study was to characterize the impact of the P-glycoprotein (P-gp) inducer, carbamazepine, on fexofenadine enantiomer pharmacokinetics. Twelve healthy volunteers initially received a 60mg dose of fexofenadine alone. Subsequently, a 100mg dose of carbamazepine was administered three times daily (300mg day(-1) ), and on day 7, fexofenadine was co-administered. Carbamazepine significantly decreased the area under the plasma concentration-time curve and the amount excreted into the urine of (S)- and (R)-fexofenadine. The P-gp inducer showed a greater effect on the pharmacokinetic parameters of (S)-fexofenadine. This study indicates that carbamazepine may alter the pharmacokinetics of fexofenadine enantiomers. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Citation

Yumiko Akamine, Masatomo Miura, Norio Yasui-Furukori, Midori Kojima, Tsukasa Uno. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. British journal of clinical pharmacology. 2012 Mar;73(3):478-81